Molecular Partners (NASDAQ:MOLN) Shares Down 0.5% - Time to Sell?

Molecular Partners AG (NASDAQ:MOLN - Get Free Report)'s share price was down 0.5% during trading on Tuesday . The company traded as low as $3.81 and last traded at $3.86. Approximately 13,897 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 19,646 shares. The stock had previously closed at $3.88.

Wall Street Analysts Forecast Growth

Separately, Lifesci Capital started coverage on Molecular Partners in a report on Tuesday, March 11th. They issued an "outperform" rating and a $12.00 target price on the stock.

Molecular Partners Stock Performance

The company has a market cap of $144.14 million, a price-to-earnings ratio of -1.66 and a beta of 1.16. The stock's fifty day moving average is $4.64 and its two-hundred day moving average is $5.13.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. On average, equities research analysts expect that Molecular Partners AG will post -1.93 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Molecular Partners stock. Suvretta Capital Management LLC boosted its position in Molecular Partners AG (NASDAQ:MOLN - Free Report) by 455.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,221,494 shares of the company's stock after buying an additional 1,821,494 shares during the quarter. Suvretta Capital Management LLC owned approximately 5.50% of Molecular Partners worth $10,548,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 26.55% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.